Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 2sodium-iodide symporter 1ruxolitinib 1glofitamab 1fludarabine 1duvelisib 1cemiplimab 1belinostat 1X-Rays 1Specimen Handling 1Positron-Emission Tomography 1Photons 1Nivolumab 1Magnetic Resonance Spectroscopy 1MAC-ST-001 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Fenretinide 1Disulfides 1CTLA-4 Antigen 1Biopsy 1Bendamustine Hydrochloride 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Immunoblastic Lymphadenopathy × 10-propargyl-10-deazaaminopterin × Clear all
NCT06561048 2026-04-08

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals, Inc.

Phase 3 Recruiting
150 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡